Abstract
Background: Endoluminal stenting for malignant bowel obstruction has a reported perforation rate of approximately 4%. Bevacizumab is a humanized monoclonal neutralizing antibody against the vascular endothelial growth factor receptor. It is a first line angiogenesis inhibitor used to treat variety of malignancies including several gastrointestinal cancers which are frequently associated with malignant bowel obstruction. Gastrointestinal perforation is a known complication of Bevacizumab. The aim of this study is to review all patients who had endoluminal stents and received Bevacizumab within sixty days of stent placement to determine the rate of immediate and delayed perforation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
